Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CLASS ACTION UPDATE for XENT, ASNA and RMED: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

VTAK

NEW YORK, NY / ACCESSWIRE / June 28, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

Intersect ENT, Inc. (NASDAQGM: XENT)

Class Period: August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=2141&wire=1

About the lawsuit: During the class period, Intersect ENT, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Intersect ENT, Inc. class action contact jlevi@levikorsinsky.com.

Ascena Retail Group, Inc. (NASDAQGS: ASNA)

Class Period: September 16, 2015 - June 8, 2017
Lead Plaintiff Deadline : August 6, 2019
Join the action: https://www.zlk.com/pslra-1/ascena-retail-group-inc-loss-form?prid=2141&wire=1

About the lawsuit: Throughout the class period, Ascena Retail Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the ANN Acquisition was a complete disaster for the Company as Ann's operations were in far worse condition than had been represented to the public; (b) in order to mask the true condition of Ann, Defendants improperly delayed recognizing an impairment charge to the value of Ann's goodwill and, as a result, Ascena's reported income and assets were materially overstated and the Company's financial results were not prepared in conformity with GAAP; (c) many of the brands acquired in the ANN Acquisition were in steep decline and were also materially overvalued on Ascena's Class Period financial statements; and (d) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company, its operations and prospects.

To learn more about the Ascena Retail Group, Inc. class action contact jlevi@levikorsinsky.com.

Ra Medical Systems, Inc. (NYSE: RMED)

Class Period: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company's September 2018 initial public offering.
Lead Plaintiff Deadline : August 6, 2019
Join the action: https://www.zlk.com/pslra-1/ra-medical-systems-inc-loss-form?prid=2141&wire=1

About the lawsuit: Ra Medical Systems, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) the Company's evaluation of sales personnel candidates was inadequate; (2) the Company's training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company's manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the Ra Medical Systems, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/550250/CLASS-ACTION-UPDATE-for-XENT-ASNA-and-RMED-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today